Last Price:
Date of Initial Coverage
01-Jan-21
Initial Entry Price
$0.029
Returns from Initial Entry
-66%
After extinguishing the company debt and ridding the company of a major con note holder we expect CPH to significantly re-rate on positive macro news or company news. [13-Oct-2020]
A few weeks after we made our Investment in CPH the US announced the MORE act which spurred the CPH share price.
The company continued to deliver on some milestones and without the selling pressure from the con note holders the share price rose 1000%+ in a short period of time.
From here we Free Carried our Investment and Took Profit - we still held on to a position in CPH to see if the company could deliver some key milestones before we announced it as a stock in our Portfolio.
The Halluanex acquisition was promising, and we were waiting to see how clinical trials would play out, however, with some recent controversy and an increasingly difficult story to follow we have decided to move CPH into our “Bottom Drawer Portfolio”.
We are now holding on to our CPH shares to see if the company can deliver on its Hallcanex project and may sell out of the stock to free up capital for other investments. We will look to reduce our position if there is an increase in the share price and liquidity in the stock.
✅ Initial Investment: @2.9c
✅ Top Slice
✅ Free Carry
✅ Increased Investment: @19c
✅ Free Carry
✅ Take Profit
✅ Price increases 300% from initial entry
✅ Price increases 500% from initial entry
✅ Price increases 1000% from initial entry
✅ 12 Month Capital Gain Discount
🔲 Hold remaining Position for next 2+ years
Discover High-Risk,
High-Reward Stocks
Join thousands of other Investors following our stock commentary for Free
